TD Private Client Wealth LLC Has $10.21 Million Position in Gilead Sciences, Inc. $GILD

TD Private Client Wealth LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 27.5% during the fourth quarter, HoldingsChannel reports. The firm owned 83,200 shares of the biopharmaceutical company’s stock after acquiring an additional 17,944 shares during the quarter. TD Private Client Wealth LLC’s holdings in Gilead Sciences were worth $10,212,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. Invesco Ltd. raised its position in shares of Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares during the period. Legal & General Group Plc raised its position in shares of Gilead Sciences by 4.2% during the third quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock worth $1,133,376,000 after purchasing an additional 414,454 shares during the period. Ameriprise Financial Inc. raised its position in shares of Gilead Sciences by 5.9% during the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock worth $793,506,000 after purchasing an additional 400,002 shares during the period. Finally, Nordea Investment Management AB raised its position in shares of Gilead Sciences by 16.5% during the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after purchasing an additional 726,101 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $129.58 on Monday. The firm has a market capitalization of $160.88 billion, a price-to-earnings ratio of 17.65 and a beta of 0.31. Gilead Sciences, Inc. has a twelve month low of $100.23 and a twelve month high of $157.29. The stock’s 50 day moving average price is $137.76 and its two-hundred day moving average price is $133.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is 44.69%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on GILD shares. Royal Bank Of Canada dropped their price target on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating on the stock in a research report on Friday, May 8th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday, February 11th. Wolfe Research raised their price target on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. Finally, Weiss Ratings raised Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, May 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $157.04.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer owned 167,779 shares in the company, valued at approximately $25,910,110.97. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the transaction, the insider owned 120,288 shares of the company’s stock, valued at $18,577,278.72. The trade was a 18.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 63,000 shares of company stock valued at $9,238,250 in the last 90 days. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.